Compare DexCom, Inc. (DXCM) vs Google Inc (GOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Google Inc — how do they compare? DexCom, Inc. trades at $83.01 (market cap $31.86B), while Google Inc trades at $348.08 (market cap $4.24T). The key difference: Google Inc is far larger — about 133.1× DexCom, Inc.'s market cap, and Google Inc pays a 0.26% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Google Inc for 137 Days on average.
| DXCM | GOOG | |
|---|---|---|
Market Cap | $31.86B | $4.24T |
Volume | 3,607,070 | 13,937,902 |
Sector | Health | Media |
52-Week High | $92.34 | $399.06 |
52-Week Low | $54.84 | $237.49 |
Typical Hold Time | 62 Days | 137 Days |
Enterprise Value | $31.32B | $4.13T |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Alphabet (GOOG) trades at $350.02, up 0.76% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional financial performance with 32.8% net margins and consistent earnings beats, though significant capital expenditures have led to negative free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target, representing 24% upside potential from current levels.
The outlook remains favorable given Alphabet's dominant market position and AI leadership, though investors face risks from escalating capital spending, regulatory scrutiny, and multiple class-action lawsuits. The stock's current valuation at 17.3x P/E appears reasonable relative to growth prospects, supported by robust cash flow generation and expanding cloud revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
